ExThera Medical’s Post

For US #HCPs at #ASCO24: don’t miss Dr. Niels Van De Donk present an updated analysis of patients receiving an IL-6R inhibiting antibody for cytokine release syndrome (CRS) prophylaxis in the Phase 1/2 MajesTEC-1 study of BCMAxCD3 bispecific antibody in patients with relapsed/refractory #MultipleMyeloma. Click here to see the presentation: https://lnkd.in/ed4-2Kg4

#Calprotectin is a heterodimer of S100A8 and S100A9 that is abundant in the #neutrophil cytoplasm and released upon proinflammatory neutrophil activation. Levels of calprotectin are higher in primary #antiphospholipid syndrome (APS) and antiphospholipid antibody (#aPL)-positive patients compared to healthy controls. Calprotectin may induce aPL-mediated #thrombocytopenia by engaging #platelet surface #TLR4 and activating the NLRP3-#inflammasome, thereby reducing platelet viability in a #caspase-1-dependent manner. This suggests that calprotectin has the potential to be a functional biomarker and a new therapeutic target for APS thrombocytopenia. 🔗https://lnkd.in/gMR2k2t3

Avalyn shared several presentations today at #ATS2024 showcasing AP01, a novel formulation of inhaled pirfenidone, for the treatment of pulmonary fibrosis. Read more about the new long-term efficacy and lung biomarker data shared today, which support the advancement of AP01 into a Phase 2b trial in progressive pulmonary fibrosis.   https://lnkd.in/g2-CQBe2 #PulmonaryFibrosis #LungDisease

Did you know that 82% of projects that utilized efficacy biomarkers have been active or successful in Phase IIa trials? * Navigating the world of biomarkers in neurological diseases like Huntington’s Disease is fraught with challenges. Yet, their impact have the potential to revolutionize drug development. Our 3rd Biomarker Discovery Spotlight, zeroing in on biomarkers for Huntington's is now available for download. Request your copy here: https://hubs.la/Q025BQwf0 #BiomarkerDiscovery #HuntingtonsDisease #DrugDevelopment * https://hubs.la/Q025BSm40

More good preclincal results for Race Oncology and their #anticancer and #cardioprotective drug #bisantrene, with results showing it to be effective in treating multiple myeloma.

So lucky to be able to work so closely with Cheerag and learn from his experience and expertise, I want to congratulate Cheerag Shirodaria on his latest publication in Cardiovascular Research. Identification and targeting coronary inflammation is an emerging strategy for reducing cardiovascular risk. This important trial, utilising Caristo’s CaRi-Heart technology, showed that Orticumab, a monoclonal antibody against oxidized low-density lipoprotein (oxLDL), a key driver of plaque inflammation and destabilization in coronary artery disease, significantly reduced coronary inflammation. Read the new peer-reviewed publication by Cheerag Shirodaria, M.D., VP and TA Head, Cardiovascular/Metabolism at Fortrea, and additional authors. #coronaryinflammation #cardiovasculardisease

We are pleased to share results of preclinical work that has found #bisantrene, as a single agent treatment, to be effective against human multiple myeloma in a mouse model and more effective in combination with the standard of care multiple myeloma proteasome inhibitor, carfilzomib. In this study, bisantrene was found to significantly slow multiple myeloma disease progression, whereas carfilzomib at the maximum tolerated dosage showed no single-agent activity. However, #carfilzomib, when combined with bisantrene, was able to slow disease progression more than bisantrene treatment alone. Race Chief Executive Officer, Dr Daniel Tillett comments: “It is always exciting to see the potential clinical utility of bisantrene grow. Carfilzomib is a highly active treatment for multiple myeloma, but it comes with very serious cardiotoxicity risks. The potential for using bisantrene to not only better treat multiple myeloma, but also protect patients from the heart damage caused by carfilzomib, is worthy of further investigation.” More details are available here: https://shorturl.at/QYgb6 #multiplemyeloma #cardioprotection

Lenvatinib + pembrolizumab showed a greater clinical benefit vs sunitinib, irrespective of patient biomarker subtype, in advanced clear cell #RCC, according to findings from phase 3 CLEAR trial. #ASCO24 https://lnkd.in/gDGHH72k

New studies highlight a promising therapeutic target in treating Idiopathic pulmonary fibrosis, a debilitating and deadly lung condition. Researchers from the Mayo Clinic have identified that the antifibrotic properties of the D1 dopamine receptor, persist even in the presence of the master regulator of fibrosis, TGF- β1. Since current available therapies only slow the disease progression, these studies D1 as a promising therapeutic target to treat IPF. Read the article here: https://bit.ly/3Zgn1ln. #Pharmacology

In the GEMSTONE-303 study, sugemalimab in combination with chemotherapy as a first-line treatment of locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma has demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) and overall survival (OS).